For research use only. Not for therapeutic Use.
Lanicemine (free base) is a low-trapping NMDA receptor antagonist. Lanicemine is used the management of severe and treatment-resistant depression. Lanicemine was originally developed as a neuroprotective agent, but was redeveloped as an antidepressant.
| Catalog Number | R024441 |
| CAS Number | 153322-05-5 |
| Synonyms | (S)-α-phenyl-2-Pyridineethanamine; AR-R 15896; ARL 15896; FPL 15896; Lanicemine |
| Molecular Formula | C13H14N2 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | (1S)-1-phenyl-2-pyridin-2-ylethanamine |
| InChI | InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1 |
| InChIKey | FWUQWDCOOWEXRY-ZDUSSCGKSA-N |
| SMILES | C1=CC=C(C=C1)C(CC2=CC=CC=N2)N |
| Reference | </br>1:Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Agbo F, Bui KH, Zhou D.J Clin Pharm Ther. 2017 May 4. doi: 10.1111/jcpt.12541. [Epub ahead of print] PMID: 28474366 </br>2:Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S.Neuropsychopharmacology. 2017 Mar;42(4):844-853. doi: 10.1038/npp.2016.224. Epub 2016 Sep 29. PMID: 27681442 Free PMC Article</br>3:Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. Downey D, Dutta A, McKie S, Dawson GR, Dourish CT, Craig K, Smith MA, McCarthy DJ, Harmer CJ, Goodwin GM, Williams S, Deakin JF.Eur Neuropsychopharmacol. 2016 Jun;26(6):994-1003. doi: 10.1016/j.euroneuro.2016.03.006. Epub 2016 Apr 28. PMID: 27133029 </br>4:Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. Bui KH, Zhou D, Agbo F, Guo J.J Clin Pharmacol. 2015 Sep;55(9):1024-30. doi: 10.1002/jcph.515. Epub 2015 Jun 2. PMID: 25880724 </br>5:Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects. Guo J, Zhou D, Grimm SW, Bui KH.Xenobiotica. 2015 Mar;45(3):244-55. doi: 10.3109/00498254.2014.966175. Epub 2014 Sep 26. PMID: 25259653 </br>6:Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC.Mol Psychiatry. 2014 Sep;19(9):978-85. doi: 10.1038/mp.2013.130. Epub 2013 Oct 15. PMID: 24126931 Free PMC Article |
